These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21128363)

  • 1. [Suspension of the commercialization of sibutramine and rosiglitazone in Europe].
    Scheen AJ
    Rev Med Liege; 2010 Oct; 65(10):574-9. PubMed ID: 21128363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European Medicines Agency withdrawal for sibutramine.
    Galhardo J; Davis N; Matthai S; Shield JP
    Arch Dis Child; 2010 Oct; 95(10):856. PubMed ID: 20573736
    [No Abstract]   [Full Text] [Related]  

  • 3. Withdrawal of sibutramine in Europe.
    Williams G
    BMJ; 2010 Feb; 340():c824. PubMed ID: 20144986
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular risk-benefit profile of sibutramine.
    Scheen AJ
    Am J Cardiovasc Drugs; 2010; 10(5):321-34. PubMed ID: 20860415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone is a valid alternative to rosiglitazone.
    Derosa G
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):357-62. PubMed ID: 21950735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sibutramine (Meridia) withdrawn.
    Med Lett Drugs Ther; 2010 Nov; 52(1350):88. PubMed ID: 21045763
    [No Abstract]   [Full Text] [Related]  

  • 7. Sibutramine: EMEA under industry's thumb.
    Prescrire Int; 2003 Jun; 12(65):102. PubMed ID: 12825579
    [No Abstract]   [Full Text] [Related]  

  • 8. The rosiglitazone decision process at FDA and EMA. What should we learn?
    Pouwels KB; van Grootheest K
    Int J Risk Saf Med; 2012; 24(2):73-80. PubMed ID: 22751189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bruising associated with sibutramine: results from postmarketing surveillance in New Zealand.
    Harrison-Woolrych M; Hill GR; Clark DW
    Int J Obes (Lond); 2006 Aug; 30(8):1315-7. PubMed ID: 16491106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [About the withdrawal of sibutramine in Peru].
    Dongo V
    Rev Peru Med Exp Salud Publica; 2010; 27(4):649-50. PubMed ID: 21308210
    [No Abstract]   [Full Text] [Related]  

  • 11. Rosiglitazone and the need for a new drug safety agency.
    Garattini S; Bertele' V
    BMJ; 2010 Oct; 341():c5506. PubMed ID: 20926483
    [No Abstract]   [Full Text] [Related]  

  • 12. European drug regulators publish their evaluation of rosiglitazone.
    Mayor S
    BMJ; 2010 Dec; 341():c7278. PubMed ID: 21169326
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sibutramine-associated psychotic symptoms and zolpidem-induced complex behaviours: implications for patient safety.
    Wiglusz MS; Cubała WJ; Nowak P; Jakuszkowiak-Wojten K; Landowski J; Krysta K
    Psychiatr Danub; 2013 Sep; 25 Suppl 2():S143-5. PubMed ID: 23995163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone: trials, tribulations and termination.
    Krentz AJ
    Drugs; 2011 Jan; 71(2):123-30. PubMed ID: 21275442
    [No Abstract]   [Full Text] [Related]  

  • 16. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
    Hiatt WR; Kaul S; Smith RJ
    N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
    [No Abstract]   [Full Text] [Related]  

  • 17. [32-year-old patient with acute myocardial infarction possibly induced by the appetite suppressant sibutramine].
    Pöss J; Böhm M; Link A
    Dtsch Med Wochenschr; 2010 May; 135(19):965-8. PubMed ID: 20446231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.
    Hall GC; Smith HT; Curtis B; McMahon AD
    Int J Clin Pract; 2011 May; 65(5):586-91. PubMed ID: 21489082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The trial that killed a drug].
    Rössner S
    Lakartidningen; 2010 Sep 29-Oct 5; 107(39):2339. PubMed ID: 20976857
    [No Abstract]   [Full Text] [Related]  

  • 20. QT interval prolongation associated with sibutramine treatment.
    Harrison-Woolrych M; Clark DW; Hill GR; Rees MI; Skinner JR
    Br J Clin Pharmacol; 2006 Apr; 61(4):464-9. PubMed ID: 16542208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.